

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1 (Currently Amended) Method for obtaining, preparing or producing human suppressor T lymphocytes ~~[[()]]~~and/or the precursors thereof~~[[()]]~~, comprising a step of selection, separation or isolation in vitro or ex vivo of human T lymphocytes expressing the THY-1 molecule.

2. (Original) Method according to claim 1, comprising:

- (a) obtaining a cell population of human origin comprising T lymphocytes, and
- (b) recovering T lymphocytes expressing the THY-1 antigen.

3. (Currently Amended) Method according to claim 1, ~~characterized in that~~ wherein the step (b) is preceded or followed by a step of amplification of T lymphocytes.

4. (Currently Amended) ~~Method according to any one of the previous claims, characterized in that~~ The method of claim 1 wherein the T lymphocytes expressing the THY-1 antigen are selected, separated, isolated or recovered by means of a ligand specific of THY-1.

5. (Currently Amended) Method according to claim 4, ~~characterized in that~~ wherein the specific ligand is an antibody specific of THY-1 or a fragment or derivative of said antibody having substantially the same antigenic specificity.

6. (Currently Amended) Method according to claim 5, ~~characterized in that~~ wherein the specific ligand is a monoclonal or polyclonal antibody specific of THY-1.

7. (Currently Amended) Method according to claim 5, ~~characterized in that~~ wherein the specific ligand is a polyfunctional, monocatenary or multimeric antibody, specific of THY-1.

8. (Currently Amended) Method according to claim 4, ~~characterized in that~~ wherein the specific ligand is an aptamer.

9. (Currently Amended) Method according to ~~any one of claims 4 to 8~~ claim 4, ~~characterized in that~~ wherein the ligand is immobilized on a support or placed in solution.

10. (Currently Amended) Method according to claim 9, ~~characterized in that~~ wherein the support is a column or a bead, preferably a magnetic bead.

11. (Currently Amended) Method according to ~~any one of claims 4 to 10~~ claim 4, ~~characterized in that~~ wherein the ligand is labelled.

12. (Currently Amended) Method according to claim 11, ~~characterized in that~~ wherein the labelling is carried out by means of a fluorescent, radioactive, luminescent, phosphorescent, chemical or enzymatic detection label.

13. (Currently Amended) Method according to ~~any one of the previous claims~~ claim 1, ~~characterized in that~~ wherein the step of recovery, selection or isolation is carried out by flow cytometry, affinity chromatography, FACS, MACS or D/MACS.

14. (Currently Amended) Method according to ~~any one of the previous claims~~ claim 2, ~~characterized in that~~ wherein the cell population comes from a tissue selected in the group consisting of bone marrow, spleen, liver, thymus, blood which has or has not been previously enriched in T lymphocytes, umbilical cord blood, fetal, infant or adult peripheral blood, a tumor, a site of inflammation, a transplanted organ or a cell culture established with one or another of said tissues.

15. (Original) Method for identifying and/or quantifying human suppressor T lymphocytes in a cell population, comprising exposing said cell population to a ligand specific of THY-1 and determining and/or quantifying the formation of a complex between the ligand and the cells, the formation of said complexes indicating the presence and/or the quantity of suppressor T lymphocytes in the cell population.

16. (Original) Method for producing a pharmaceutical composition, comprising:

- (a) obtaining a biological sample comprising human T lymphocytes,
- (b) selecting T lymphocytes expressing the THY-1 antigen in said biological sample,

and

- (c) conditioning said T lymphocytes expressing the THY-1 antigen in a pharmaceutically acceptable adjuvant or medium.

17. (Original) Method for producing a pharmaceutical composition, comprising :

- (a) obtaining a biological sample comprising human T lymphocytes,
- (b) depleting T lymphocytes expressing the THY-1 antigen from said biological sample, and

- (c) conditioning said T lymphocytes not expressing the THY-1 antigen in a pharmaceutically acceptable adjuvant or medium.

Claims 18-28 (Canceled)